• Significant improvement in Overall Response Rate (83%) compared with matched case control group (45%).
• Significant overall survival advantage, with a 46% reduction in the risk of death.
• Excellent safety profile and significant efficacy bolster HaemaLogiX's plan to progress further KappaMab / standard of care combination studies.

SYDNEY, June 29, 2023...